STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more

Patient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drug.

The drug, called Ingrezza, is approved to treat a movement disorder called tardive dyskinesia, but some patients and doctors are reporting serious side effects.

Meanwhile, pharma payments to doctors are under scrutiny, with a new study finding that industry-sponsored meals and speaking fees may influence prescribing habits.